Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic

Oncoimmunology. 2015 Mar 19;4(6):e1008858. doi: 10.1080/2162402X.2015.1008858. eCollection 2015 Jun.

Abstract

The active Th1/CTL immune microenvironment of Microsatellite Instable colorectal cancer (CRC) is counterbalanced by up-regulated expression of multiple immune checkpoints, suggesting that defective mismatch repair may be a biomarker to select CRC patients for treatment with checkpoint inhibitors. This hypothesis is currently being tested in two clinical trials.